PDF(Pubmed)
Abstract：
Many countries have adopted higher-valent pediatric combination vaccines to simplify vaccination schedules and minimize health expenditures and social costs. However, China is conservative in the use of pediatric combination vaccines. By reviewing and synthesizing quantitative and qualitative data, in this commentary we identify gaps and challenges to combination vaccine use and make recommendations for promoting use of higher-valent pediatric combination vaccines in China. Challenges are in four dimensions: (1) legislation and regulation, (2) immunization schedule design, (3) vaccine awareness and price, and (4) research and development capacity. To optimize the use of combination vaccines to reduce vaccine-preventable disease burden, we make recommendations that address key challenges: (1) develop policies and regulations to strengthen enforcement of the Vaccine Administration Law and remove regulatory hurdles that hinder combination vaccine research and development, (2) establish an evidence-informed policy-making mechanism for combination vaccines, (3) resolve immunization schedule conflicts between monovalent and combination vaccines, and (4) implement effective interventions to increase vaccine awareness and reduce price.
摘要：
许多国家已经采用了更高价的儿科联合疫苗，以简化疫苗接种时间表并最大程度地减少卫生支出和社会成本。然而,中国在儿童联合疫苗的使用上是保守的。通过审查和综合定量和定性数据，在这篇评论中,我们确定了联合疫苗使用的差距和挑战,并就在中国推广使用更高价的儿科联合疫苗提出了建议.挑战体现在四个方面:(1)立法和监管,(2)免疫计划设计,（3）疫苗意识和价格，（四）研发能力。优化组合疫苗的使用，以减少疫苗可预防的疾病负担，我们提出应对主要挑战的建议：（1）制定政策和法规，以加强《疫苗管理法》的执行，并消除阻碍联合疫苗研发的监管障碍，(2)建立联合疫苗循证决策机制,（3）解决单价疫苗和联合疫苗之间的免疫计划冲突，(4)实施有效的干预措施，提高疫苗意识，降低价格。
